| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.11 | 0.05 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.067 | 0.05 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.063 | 0.05 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.071 | 0.05 |
| mRNA | NSC-87877 | GDSC1000 | pan-cancer | AAC | -0.067 | 0.06 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.06 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.063 | 0.06 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.06 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.11 | 0.06 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.096 | 0.06 |